American Review of Respiratory Disease · 1993 · 104 citations · 28 references
MedicinePharmacologyBiochemical PharmacologyMolecular PharmacologyPharmacodynamicsPharmacodynamics Across SpeciesRespiratory PharmacologyAntagonist ActivityDose-dependent SelectivityGuinea Pig ModelsInhibitor SpecificityIntraperitoneal AdministrationPharmacologic Cough TreatmentPretreatmentSubstance P Pharmacology
We examined an endogenous substance causing cough in awake guinea pigs. An intraperitoneal injection of phosphoramidon, a selective inhibitor of neutral endopeptidase (E.C. 3.4.24.11), caused cough in a dose-dependent fashion for approximately 40 min. At a dose of 3 x 10(-3) mol/kg, phosphoramidon caused a total of 11.6 +/- 1.4 coughs in 40 min. Phosphoramidon (3 x 10(-3) mol/kg)-induced cough was significantly inhibited by systemic pretreatment with capsaicin (p < 0.01). Aerosols of FK 888 (1 min), a specific inhibitor of substance P (NK1) receptor, inhibited phosphoramidon (3 x 10(-3) mol/kg)-induced cough in a dose-dependent fashion with complete inhibition at a dose of 10(-5) M. Likewise, aerosols of FK 224 (10(-5) M; 1 min), another inhibitor of NK1 and NK2 receptors, or lidocaine (4%, 1 min) significantly inhibited phosphoramidon (3 x 10(-3) mol/kg)-induced cough (p < 0.01). Furthermore, aerosols of FK 888 (10(-5) M; 1 min) significantly inhibited cough induced by cigarette smoke in awake guinea pigs (p < 0.01). These results suggest that substance P released from sensory nerves in the airway may be an endogenous substance causing cough and the substance P antagonist may be the drug for treatment of cough in respiratory disease.
28
F. Plum · Archives of Neurology · 1960 · 10.4K citations
Substance P: Localization in the Central Nervous System and in Some Primary Sensory Neurons
Tomas Hökfelt, J.‐O. Kellerth, Göran Nilsson et al. · Science · 1975 · 1K citations
ANGIOTENSIN-CONVERTING ENZYME AND THE COUGH REFLEX
AlynH. Morice, MorrisJ. Brown, Rachel Lowry et al. · The Lancet · 1987 · 749 citations